Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127
جيلاد سينسيس
Gilead Sciences, Inc. GILD | 0.00 |
Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:
GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.
